Literature DB >> 1540204

Biodistribution and toxicity of 2,4-divinyl-nido-o-carboranyldeuteroporphyrin IX in mice.

M Miura1, P L Micca, J C Heinrichs, D Gabel, R G Fairchild, D N Slatkin.   

Abstract

BALB/c mice with transplanted subcutaneous KHJJ mammary carcinomas were given 2,4-divinyl-nido-o-carboranyldeuteroporphyrin IX (VCDP), a prospective boron carrier for boron neutron-capture therapy, to determine the dose schedule that results in maximal boron uptake in tumor. A total dose of 270 +/- 10 micrograms/g body weight given in a 4-day multiple intraperitoneal injection schedule (3/day) resulted in 30-50 micrograms boron/g tumor. After such a dose, thrombocytopenia, granulocytosis and altered liver enzyme levels were measured in the blood. Blood boron clearance was followed for an 18 hr to 6 day post-injection period. Toxic effects of VCDP subsided within 4-6 days after the last injection. In view of the greater than 30 micrograms/g peak accumulation of boron in tumor from VCDP and the subsequent rapid reversal of VCDP toxicity, further studies of VCDP in small mammals relevant to its distribution, toxicity and potential clinical use for neutron-capture therapy of tumors appear warranted.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540204     DOI: 10.1016/0006-2952(92)90565-z

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  2 in total

Review 1.  Boron Neutron Capture Therapy: Current Status and Challenges.

Authors:  Song Wang; Zhengchao Zhang; Lele Miao; Yumin Li
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

2.  Hemorrhage in mouse tumors induced by dodecaborate cluster lipids intended for boron neutron capture therapy.

Authors:  Tanja Schaffran; Nan Jiang; Markus Bergmann; Ekkehard Küstermann; Regine Süss; Rolf Schubert; Franz M Wagner; Doaa Awad; Detlef Gabel
Journal:  Int J Nanomedicine       Date:  2014-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.